

## 測試報告

報告編號： PUF20A00237

日期： 2020年10月29日

頁數： 1 of 9



冠泰藥業有限公司

臺中市西區民權路185號10樓之11室

以下測試之樣品係由申請廠商所提供及確認：

產品名稱： 冠泰補益多血紅素軟膠囊  
申請廠商： 冠泰藥業有限公司  
申請廠商地址： 臺中市西區民權路185號10樓之11室  
電話/聯絡人： 04-22202275/冠泰藥業有限公司  
樣品包裝： 請參考報告末頁樣品照片  
數量： 共6包  
樣品保存方式： 室溫  
產品型號： ---  
產品批號： 22006132  
製造/國內負責廠商： VIVA PHARMACEUTICAL INC.  
製造日期： ---  
有效期限： 2024/07/16  
收樣日期： 2020年10月15日  
測試日期： 2020年10月15日 ~ 2020年10月29日  
測試結果： -請見下頁-

陳新智  
SGS TAIWAN LTD  
SGS  
TAIWAN  
陳新智 經理  
台灣檢驗科技股份有限公司  
報告簽署人

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUF20A00237

日期： 2020年10月29日

頁數： 2 of 9



冠泰藥業有限公司

臺中市西區民權路185號10樓之11室

測試結果：

測試項目	測試方法	測試結果	定量/偵測極限	單位
西藥成分定性分析360項	---	---	---	---
本樣品檢測共360項西藥(項目詳見附錄)	本測試依實驗室內部方法(TESP-UB-0173, TESP-UB-0181, TESP-UB-0182), 以薄層層析法(TLC), 液相層析離子阱質譜儀(LC/MS/MS)或氣相層析質譜儀(GC/MS)檢測。	N.D.	---	ppm(µg/g)

備註：

1. 測試報告僅就委託者之委託事項提供測試結果，不對產品合法性做判斷。
2. 本測試報告之所有檢驗內容，均依委託事項執行檢驗，如有不實，願意承擔完全責任。
3. 本報告不得分離，分離使用無效。
4. 若該測試項目屬於定量分析則以「定量極限」表示；若該測試項目屬於定性分析則以「偵測極限」表示。
5. 低於定量極限/偵測極限之測定值以「N.D.」或「陰性」表示。微生物測試低於定量極限以「<定量極限值」表示。

- END -

測試報告

報告編號： PUF20A00237

日期： 2020年10月29日

頁數： 3 of 9



冠泰藥業有限公司

臺中市西區民權路185號10樓之11室

附 錄

360項西藥測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu$ g/g)

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
2,4-Dinitrophenol	51-28-5	3600	Benzbromarone	3562-84-3	900
2-Diphenylmethylpyrrolidine	22348-31-8	150	Benzhexol	144-11-6	1800
7-keto-Dehydroepiandrosterone	566-19-8	3000	Benzocaine	94-09-7	300
Acetaminophen	103-90-2	300	Benzydamine	642-72-8	348
Acetil acid	147676-78-6	1500	貝他美沙松	378-44-9	900
Acetildenafil	831217-01-7	600	Betamethasone 21 Acetate	987-24-6	4500
Acetohexamide	968-81-0	750	Betamethasone Benzoate	22298-29-9	3225
Acetophenetidin	62-44-2	3600	Betamethasone Dipropionate	5593-20-4	1050
Acetylvardenafil	1261351-28-3	600	Betamethasone Valerate	2152-44-5	108
Acrinol	1837-57-6	2832	Bezafibrate	41859-67-0	600
Allopurinol	315-30-0	600	Bisacodyl	603-50-9	600
Ambroxol	18683-91-5	600	Bisoprolol Fumarate	104344-23-2	60
Aminophylline	317-34-0	4500	Bromhexine	3572-43-8	1200
Aminopyrine	58-15-1	900	Bromopride	4093-35-0	60
Aminotadalafil	385769-84-6	900	Brompheniramine	86-22-6	1800
Amitriptyline	549-18-8	750	Bromvalerylurea	496-67-3	1950
Amlodipine	88150-42-9	300	Bucetin	1083-57-4	600
Amoxicillin	26787-78-0	4320	Bufexamac	2438-72-4	1650
Amphetamine	300-62-9	375	Buspirone	36505-84-7	3600
Ampicillin	69-53-4	2700	Butropium	107080-63-7	3000
Apomorphine	58-00-4	600	咖啡因	58-08-2	600
Aspirin	50-78-2	600	Camylofine	54-30-8	3000
Astemizole	68844-77-9	150	Carbamazepine	298-46-4	3600
Atenolol	29122-68-7	300	Carbetapentane	77-23-6	150
Atorvastatin	134523-00-5	420	Carbimazole	22232-54-8	600
Atropine	51-55-8	150	Carbinoxamine	486-16-8	1650
Baclofen	1134-47-0	300	Carbodenafil	944241-52-5	1500
Barbital	57-44-3	750	Carisoprodol	78-44-4	375
Benazepril	86541-75-5	450	Carvedilol	72956-09-3	2400
Benproperine	2156-27-6	2400	Cefamandole nafate	42540-40-9	150
Benzathine-penicillin	41372-02-5	3300	Cefazolin	25953-19-9	1050

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUF20A00237

日期： 2020年10月29日

頁數： 4 of 9



冠泰藥業有限公司

臺中市西區民權路185號10樓之11室

附 錄

360項西藥測試項目及偵測極限(LOD)彙整表：

單位： ppm(µg/g)

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Cefoperazone dihydrate	113826-44-1	300	Clotrimazole	23593-75-1	3000
Cefotaxime	63527-52-6	150	Cloxacillin Sodium	7081-44-9	4770
Ceftriaxone	73384-59-5	4224	Clozapine	5786-21-0	3000
Celecoxib	169590-42-5	3000	Cocaine	50-36-2	750
Cephalexin	15686-71-2	75	Colchicine	64-86-8	750
Cephradine	38821-53-3	81	Cortisone	53-06-5	750
Cetilistat	282526-98-1	1500	Cortisone acetate	50-04-4	3600
Cetirizine	83881-51-0	159	Cyproheptadine	129-03-3	60
Chloramphenicol	56-75-7	1200	Desacetyl diltiazem	42399-40-6	60
Chlordiazepoxide	58-25-3	300	地塞米松	50-02-2	1200
葡萄糖酸赫洛西定	55-56-1	2400	Dexamethasone phosphate	312-93-6	900
Chlormezanone	80-77-3	60	Dextromethorphan	125-71-3	1500
Chloropretadalafil	171489-59-1	1500	Diazepam	439-14-5	300
Chlorothiazide	58-94-6	750	Dibucaine	85-79-0	450
Chlorpheniramine	113-92-8	1200	Diclofenac	15307-86-5	600
Chlorpromazine	50-53-3	300	Dicyclomine	77-19-0	375
Chlorpropamide	94-20-2	600	Diethylpropion	39648-50-5	450
Chlortetracycline	57-62-5	600	己烯雌酚	56-53-1	600
Chlorzoxazone	95-25-0	1050	Difloxacin	98106-17-3	3000
Cimetidine	51481-61-9	1500	Digitoxin	71-63-6	450
Cinnarizine	298-57-7	600	Dihydroergotamine	511-12-6	150
Ciprofloxacin(CFA)	85721-33-1	240	Diltiazem	42399-41-7	300
Clenbuterol	21898-19-1	900	Dimenhydrinate	523-87-5	150
Clindamycin HCl	21462-39-5	456	Dimethylsildenafil	496835-35-9	3000
Clindamycin phosphate	24729-96-2	150	Dimetridazole	551-92-8	150
Clobenzorex	13364-32-4	375	Diphenhydramine	58-73-1	375
丙酸氯倍他素	25122-46-7	2400	Diphenylhydantoin	57-41-0	150
Clofibrate	637-07-0	1500	Diprophylline	479-18-5	900
Clonazepam	1622-61-3	150	Dipyridamole	58-32-2	450
Clonidine	4205-90-7	300	Dipyrrone	68-89-3	600
Cloperastine	3703-76-2	1500	Dithio-desmethyl-carbodenafil	1333233-46-7	1500

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUF20A00237

日期： 2020年10月29日

頁數： 5 of 9



冠泰藥業有限公司

臺中市西區民權路185號10樓之11室

附 錄

360項西藥測試項目及偵測極限(LOD)彙整表：

單位： ppm(µg/g)

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Doxazosin	74191-85-8	2400	Fluoxymesterone	76-43-7	600
Doxycycline	564-25-0	576	Flurbiprofen	5104-49-4	150
Doxylamine	469-21-6	60	Fluvastatin	93957-54-1	1200
Dyclonine Hydrochloride	536-43-6	3600	Furosemide	54-31-9	600
Econazole	27220-47-9	150	Gemfibrozil	25812-30-0	4500
Enrofloxacin	93106-60-6	3090	Gendenafil	147676-66-2	3000
Eprazinone	10402-90-1	300	Glibenclamide	10238-21-8	4800
Erythromycin	114-07-8	240	Glimepiride	93479-97-1	2400
Estazolam	29975-16-4	60	Glipizide	29094-61-9	3000
雌二醇	50-28-2	1200	Glycopyrronium	740028-90-4	900
雌二醇苯甲酸酯	50-50-0	600	Griseofulvin	126-07-8	450
雌三醇	50-27-1	60	Guaifenesin	93-14-1	2400
雌酮	53-16-7	30	Haloperidol	52-86-8	1620
炔雌醇	57-63-6	30	Homatropine	87-00-3	150
Ethisterone	434-03-7	600	Homosildenafil	642928-07-2	1350
Ethoxybenzamide	938-73-8	600	Hydralazine	86-54-4	450
Ethylestrenol	965-90-2	30	Hydrochlorothiazide	58-93-5	600
Etodolac	41340-25-4	600	皮質醇	50-23-7	750
Etofibrate	31637-97-5	3000	Hydroxyacetildenafil	147676-56-0	600
Famotidine	76824-35-6	2400	Hydroxyhomosildenafil	139755-85-4	1200
Fenbufen	36330-85-5	1875	Hydroxythiohomosildenafil	479073-82-0	1650
Fenfluramine	458-24-2	375	Hydroxyvardenafil	224785-98-2	1500
Fenofibrate	49562-28-9	150	Ibuprofen	15687-27-1	1200
Fenoterol	13392-18-2	750	Imidazosagatriazinone	139756-21-1	1200
Finasteride (Proscar)	98319-26-7	3000	Imipramine	50-49-7	60
Flavoxate	15301-69-6	900	Indapamide	26807-65-8	2400
Flibanserin	167933-07-5	3600	Indomethacin	53-86-1	1200
Fluconazole	86386-73-4	480	Isoniazid	54-85-3	302.4
Flufenamic acid	530-78-9	4050	Ketoconazole	65277-42-1	300
Fluocinonide	356-12-7	3600	Ketoprofen	22071-15-4	450
Fluoxetine	54910-89-3	1200	Ketotifen fumarate	34580-14-8	60

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUF20A00237

日期： 2020年10月29日

頁數： 6 of 9



冠泰藥業有限公司

臺中市西區民權路185號10樓之11室

附 錄

360項西藥測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu\text{g/g}$ )

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Lidocaine	137-58-6	60	Minocycline	10118-90-8	750
Lincomycin	154-21-2	1710	Minoxidil	38304-91-5	600
Liothyronine	6893-02-3	3600	Morphine	57-27-2	150
Lomefloxacin	98079-51-7	1500	Nalidixic acid	389-08-2	300
Lorazepam	846-49-1	300	Naloxone	465-65-6	384
Lorcaserin	616202-92-7	60	Naltrexone	16590-41-3	2370
Maprotiline	10262-69-8	150	Nandrolone	434-22-0	750
Mazindol	22232-71-9	1950	Naphazoline Hydrochloride	835-31-4	300
Meclizine	569-65-3	60	Naproxen	22204-53-1	900
Mefenamic acid	61-68-7	900	N-Desethylvardenafil	448184-46-1	3000
褪黑激素	73-31-4	1200	N-Desmethylacetildenafil	147676-55-9	3000
Meloxicam	71125-38-7	4500	N-Desmethylsibutramine	168835-59-4	3000
Meperidine	57-42-1	150	N-Desmethylsildenafil	139755-82-1	3000
Mephenesin	59-47-2	150	N-Didesmethylsibutramine	84467-54-9	3000
Mephentermine	100-92-5	240	Nefopam	13669-70-0	3600
Meprobamate	57-53-4	375	Nicametate	3099-52-3	2550
Metformin	657-24-9	300	Nicotine	54-11-5	60
Methamphetamine	537-46-2	750	Nifedipine	21829-25-4	600
Methandriol	521-10-8	2400	Nifuroxazide	965-52-6	540
Methandrostenolone	72-63-9	600	Nitrazepam	146-22-5	600
Methaqualone	72-44-6	900	Nitrofurantoin	67-20-9	450
Metharbital	50-11-3	750	Nitrofurazone	59-87-0	4410
Methimazole	60-56-0	300	Noracetildenafil	949091-38-7	300
Methyl DOPA-Sesquihydrate	41372-08-1	1620	Noraminyprine	519-98-2	2400
甲基培尼皮質醇	83-43-2	750	Norethisterone	68-22-4	600
Methyltestosterone	58-18-4	600	Norfloracin	70458-96-7	300
Metoclopramide	364-62-5	750	Norfludiazepam	2886-65-9	150
Metoprolol	51384-51-1	150	Norgestrel	6533-00-2	3000
Metronidazole	443-48-1	900	Norneosildenafil	371959-09-0	1000
Mexiletine	31828-71-4	1500	Nortadalafil	171596-36-4	1500
Midazolam	59467-70-8	60	Noscapine	128-62-1	300

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.



測試報告

報告編號： PUF20A00237

日期： 2020年10月29日

頁數： 7 of 9



冠泰藥業有限公司

臺中市西區民權路185號10樓之11室

附 錄

360項西藥測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu$ g/g)

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Nylidrin	849-55-8	4500	Prazosin	19216-56-9	300
Ofloxacin	82419-36-1	1920	去氫皮甯醇	50-24-8	1200
Omeprazole	73590-58-6	2400	去氫皮脂醇	53-03-2	750
Orlistat	96829-58-2	375	Prilocaine	721-50-6	4800
Orphenadrine	83-98-7	300	Primidone	125-33-7	30
Oxeladin	468-61-1	120	Probenecid	57-66-9	900
Oxethazaine	126-27-2	150	Procaine	59-46-1	300
Oxybutynin	5633-20-5	4635	黃體酮	57-83-0	600
Oxymetholone	434-07-1	1050	Promethazine	60-87-7	300
Oxyphenbutazone	129-20-4	450	Propafenone	54063-53-5	2400
Oxyphencyclimine	125-53-1	75	Propantheline	298-50-0	3000
Oxytetracycline (OTC)	79-57-2	960	Propranolol	525-66-6	1350
Papaverine	58-74-2	1560	Propyphenazone	479-92-5	3000
Pentazocine	359-83-1	30	Quetiapine	111974-69-7	2400
Pentobarbital	76-74-4	150	Quinine	130-95-0	300
Pentoxifylline	6493-05-6	2400	Ranitidine	66357-59-3	600
Phenacetin	62-44-2	3600	Reserpine	50-55-5	1200
Phenazopyridine	94-78-0	750	Rifampin	13292-46-1	120
Phenformin	114-86-3	900	Rimonabant	168273-06-1	3000
Phenobarbital	50-06-6	900	Rosiglitazone	122320-73-4	3000
酚酞	77-09-8	600	Salbutamol	18559-94-9	37.5
Phentermine	122-09-8	1500	Salicylamide	65-45-2	600
Phentolamine	50-60-2	1500	水楊酸	69-72-7	900
Phenylbutazone	50-33-9	750	Santonin	481-06-1	450
Phenylephrine	59-42-7	2850	Scopolamine	6533-68-2	150
Phenylpropanolamine	14838-15-4	60	Secobarbital	76-73-3	900
Pioglitazone	111025-46-8	1200	Sibutramine	106650-56-0	1200
Piperiacetildenafil	147676-50-4	3000	Sildenafil	139755-83-2	1200
Piperidenafil	224788-34-5	1500	Simvastatin	79902-63-9	600
Pirenzepine	28797-61-7	1350	Stanozolol	10418-03-8	2100
Piroxicam	36322-90-4	600	Strychnine	57-24-9	900

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUF20A00237

日期： 2020年10月29日

頁數： 8 of 9



冠泰藥業有限公司

臺中市西區民權路185號10樓之11室

附 錄

360項西藥測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu\text{g/g}$ )

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Sulfadiazine	68-35-9	600	Tetramethylpyrazine	1124-11-4	2400
Sulfadimethoxine	122-11-2	750	Theobromine	83-67-0	600
Sulfamerazine	127-79-7	450	Theophylline	58-55-9	600
Sulfamethazine	57-68-1	600	Thiodimethylsildenafil	856190-47-1	450
Sulfamethizole	144-82-1	600	Thiohomosildenafil	479073-80-8	450
Sulfamethoxazole	723-46-6	600	Thioridazine	50-52-2	300
Sulfamethoxypyridazine	80-35-3	450	Thiosildenafil	479073-79-5	450
Sulfamonomethoxine	1220-83-3	4650	Tiletamine	14176-49-9	300
Sulfanilamide	63-74-1	375	Timolol Maleate	26921-17-5	150
Sulfapyridine	144-83-2	2400	Tinidazole	19387-91-8	900
Sulfaquinoxaline	59-40-5	4740	Tolbutamide	64-77-7	375
Sulfathiazole	72-14-0	600	Trazodone hydrochloride	19794-93-5	3000
Sulfinpyrazone	57-96-5	750	氟脛脫氫皮質脂醇	124-94-7	900
Sulfisomidine	515-64-0	3000	Triamcinolone acetone	76-25-5	4800
Sulfisoxazole	127-69-5	450	Triazolam	28911-01-5	150
Sulindac	38194-50-2	750	Trimethoprim	738-70-5	300
Sulpiride	15676-16-1	1140	Tripolidine	486-12-4	60
Synephrine	94-07-5	450	Usnic acid	125-46-2	3600
Tadalafil	171596-29-5	600	Vardenafil	224785-90-4	1800
Terbinafine	91161-71-6	300	Vardenafil analogue(分子量312.37)	224789-21-3	1800
Terfenadine	50679-08-8	450	Verapamil	152-11-4	60
Testosterone	58-22-0	600	Xanthinol Niacinate	437-74-1	1050
丙酸鞣固酮	57-85-2	3000	Yohimbine	146-48-5	1500
Tetracaine	94-24-6	600	Zolazepam HCl	31352-82-6	60
Tetracycline	60-54-8	750	Zolpidem	82626-48-0	300

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.



## 測試報告

報告編號： PUF20A00237

日期： 2020年10月29日

頁數： 9 of 9



冠泰藥業有限公司

臺中市西區民權路185號10樓之11室

## 樣品照片

# PUF20A00237



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.